Prasinezumab
Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research[1].
Product Specifications
CAS Number
1960462-19-4
Product Name Alternative
PRX 002; RG 7935; RO 7046015
UNSPSC
12352203
Target
α-synuclein
Type
Inhibitory Antibodies
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/prasinezumab.html
Purity
99.90
Solubility
10 mM in DMSO
Smiles
[Prasinezumab]
Molecular Weight
(145.26 kDa)
References & Citations
[1]Gennaro Pagano, et al. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA) : Rationale, Design, and Baseline Data. Front Neurol. 2021 Oct 1;12:705407.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Isoform
α-synuclein Aggregation
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
RR203450L4V 200 µL
Slc2a1 (NM_138827) Rat Tagged ORF Clone Lentiviral Particle
Sign In for Pricing
View Details 